Application of ESCAT and OncoKB scales in liquid biopsy (LB) in advanced NSCLC patients (pts): Is it feasible and reliable?
Michael G. McCusker(University of Maryland, Baltimore), Christian Rolfo(University of Maryland, Baltimore), Alessandro Russo(Humanitas University), Katherine A. Scilla(University of Maryland, Baltimore), J. Chen(University of Maryland, Baltimore), Ranee Mehra(University of Maryland, Baltimore)
Cited by 2
Related Papers
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort
|Journal of Clinical Oncology|2016|859
Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer
|Journal of Clinical Oncology|2011|551
Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012
|British Journal of Cancer|2018|457
RET fusions in solid tumors
|Cancer Treatment Reviews|2019|256